Extended lamivudine treatment in patients with HBeAg negative HBVDNA positive chronic hepatitis B (CHB)

被引：0
|
作者：
Tassopoulos, NC
Anagnostopoulos, GD
Delladetsima, JK
Barbati, C
Angelopoulou, P
Sipsa, V
Hatzakis, A
机构：
[1] Western Attica Gen Hosp, Athens, Greece
[2] Laikon Gen Hosp, Athens, Greece
[3] Red Cross Gen Hosp, Athens, Greece
[4] Univ Athens, Sch Med, GR-11527 Athens, Greece
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1187
引用
收藏
页码：456A / 456A
页数：1
相关论文
共 50 条
  • [31] Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B
    Yurdaydin, C
    Bozkaya, H
    Çetinkaya, H
    Sahin, T
    Karaoguz, D
    Törüner, M
    Erkan, Ö
    Heper, AO
    Erden, E
    Bozdayi, AM
    Uzunalimoglu, Ö
    JOURNAL OF VIRAL HEPATITIS, 2005, 12 (03) : 262 - 268
  • [32] Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB)
    Jacobson, Ira M.
    Marcellin, Patrick
    Heathcote, Jenny
    Mathurin, Philippe
    Gane, Ed J.
    Buggisch, Peter
    Husa, Petr
    Krastev, Zahary
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Rousseau, Franck
    GASTROENTEROLOGY, 2009, 136 (05) : A867 - A867
  • [33] A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    Chang, TT
    Gish, RG
    de Man, R
    Gadano, A
    Sollano, J
    Chao, YC
    Lok, AS
    Han, KH
    Goodman, Z
    Zhu, J
    Cross, A
    DeHertogh, D
    Wilber, R
    Colonno, R
    Apelian, D
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10): : 1001 - 1010
  • [34] HBeAg negative patients with chronic hepatitis B are less likely to have a biochemical breakthrough during lamivudine treatment
    Akarca, US
    Gunsar, F
    Ersoz, G
    Ozacar, T
    Erensoy, S
    Akyildiz, M
    Kasap, E
    Akay, S
    Tekin, F
    Karasu, Z
    Batur, Y
    Ilter, T
    JOURNAL OF HEPATOLOGY, 2005, 42 : 170 - 170
  • [35] Treatment withdrawal after two years of lamivudine therapy in Chinese patients with HBeAg negative chronic hepatitis B
    Fung, S
    Wong, F
    Hussain, M
    Lok, AS
    HEPATOLOGY, 2002, 36 (04) : 637A - 637A
  • [36] Efficacy of the treatment of HBeAg-negative chronic hepatitis B patients with lamivudine: Results of 12 month therapy
    Seliverstova, T
    Isakov, V
    Bogomolov, P
    Mironova, O
    Pavlova, T
    Tsodikov, G
    Guschin, A
    HEPATOLOGY, 2002, 36 (04) : 637A - 637A
  • [37] Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naive Patients with HBeAg Positive Chronic Hepatitis B
    Kim, In Hee
    Lee, Seok
    Kim, Seong Hun
    Kim, Sang Wook
    Lee, Seung Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    Choi, Chang Soo
    Kim, Haak Cheoul
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (05) : 738 - 745
  • [38] Comparison of lamivudine monotherapy with lamivudine plus interferon alpha combination in patients with HBeAg positive chronic hepatitis B
    Karasu, Z
    Ersoz, C
    Akarca, U
    Gunsar, F
    Vardar, R
    Batur, Y
    JOURNAL OF HEPATOLOGY, 2001, 34 : 177 - 178
  • [39] Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance
    Perrillo, Robert P.
    Hann, Hie-Won
    Schiff, Eugene
    Mutimer, David
    Willems, Bernard
    Leung, Nancy
    Lee, William M.
    Dixon, Susan
    Woessner, Mary
    Brosgart, Carol L.
    Condreay, Lynn D.
    Gardner, Stephen D.
    HEPATOLOGY INTERNATIONAL, 2011, 5 (02) : 654 - 663
  • [40] Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance
    Robert P. Perrillo
    Hie-Won Hann
    Eugene Schiff
    David Mutimer
    Bernard Willems
    Nancy Leung
    William M. Lee
    Susan Dixon
    Mary Woessner
    Carol L. Brosgart
    Lynn D. Condreay
    Stephen D. Gardner
    Hepatology International, 2011, 5 : 654 - 663
12345